Clinical Trial Update: Individual Patient Expanded Access-Glembatumumab Vedotin

View source ↗

Summary

Expanded access program for glembatumumab vedotin in metastatic gpNMB-expressing triple-negative breast cancer is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Glembatumumab Vedotin (glembatumumab vedotin)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Metastatic gpNMB Expressing Triple Negative Breast Cancer | Status: NO_LONGER_AVAILABLE